340B Needs to Be Regulated

For the last several months, the United States House Ways and Means Committee has been holding a series of hearings to explore rising healthcare costs; 340B has been named as a key culprit. The 340B program was initially established to provide discounts on drugs to clinics, hospitals, and other covered entities that serve uninsured populations. But in 2026, few 340B entities are actually passing these discounts onto their patients. There has been an exorbitant increase in 340B spending since 2010, with the growth leading to abuse of the program and an increasing lack of transparency in reporting. The Committee hearing represented a dire need for reform of 340B on the federal level so the program can once again help patients in need. Our Health Equity advocates for large scale reforms to the 340B program that ensure patients have access to the medicine they need at a reasonable price. Read more here.